IL1B and Alzheimer disease: In the SNc, despite the levels of IL-1β and IL-6 were still higher in the 6-OHDA-injected AD-16-treated group (IL-1β: 6-OHDA + VEH: 2.84 ± 0.17; 6-OHDA + AD-16: 2.81 ± 0.12; p = 0.896; IL-6: 6-OHDA + VEH: 3.42 ± 0.08; 6-OHDA + AD-16: 3.37 ± 0.08; p = 0.782), a decrease in IL-1α (6-OHDA + VEH: 4.40 ± 0.34; 6-OHDA + AD-16: 2.54 ± 0.76; p = 0.013) and TNF-α (6-OHDA + VEH: 0.78 ± 0.02; 6-OHDA + AD-16: 0.69 ± 0.03; p = 0.026) was observed in AD-16-treated animals.